Amgen Inc. (AMGN) FY2026 Q1 P&L / Income Statement

Amgen Inc. (AMGN) FY2026 Q1 P&L / Income Statement

Income statement for 2026-01-01 through 2026-03-31. View: Product and service (2 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

8,618,000,000 US dollars

Cost of sales

2,744,000,000 US dollars

Gross profit (calculated)

5,874,000,000 US dollars

Operating expenses (calculated)

3,208,000,000 US dollars

Operating income

2,666,000,000 US dollars

Other income (expense), net (calculated)

negative 582,000,000 US dollars

Income before income taxes

2,084,000,000 US dollars

Provision for income taxes

265,000,000 US dollars

Net income

1,819,000,000 US dollars

Product sales

8,218,000,000 US dollars

Other revenues

400,000,000 US dollars

Selling, general and administrative

1,602,000,000 US dollars

Research and development

1,719,000,000 US dollars

Other

negative 113,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.